Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights before open of US markets on Thursday, August 8, 2024.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Contact:

Olivia Manser+44 (0) 7780 471568 o.manser@autolus.com

Julia Wilson +44 (0) 7818 430877 j.wilson@autolus.com

Susan A. Noonan S.A. Noonan Communications +1-917-513-5303 susan@sanoonan.com

Autolus Therapeutics (NASDAQ:AUTL)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Autolus Therapeutics.
Autolus Therapeutics (NASDAQ:AUTL)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Autolus Therapeutics.